Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Strategic selection of MDM2 inhibitors enhances the efficacy of FAK inhibition in mesothelioma based on TP53 genotype.

PloS one - 1 Jan 2026

Ning Xuerao, Nguyễn Thảo Thi Thanh, Morinaga Takao, Tada Yuji, Shimada Hideaki, Hiroshima Kenzo, Yamaguchi Naoto, Tagawa Masatoshi

Abstract excerpt

Mesothelioma has characteristic genetic changes including inactivation of neurofibromatosis type 2 (NF2) and deletion of the INK4A/ARF region. Cells deficient of NF2 protein (MERLIN) depend on focal adhesion kinase (FAK) for cell adhesion and FAK inhibitors suppress the cell growth. The INK4A/ARF deletion activates MDM2 functions which ubiquitinate and degrade p53, and consequently the cellular p53 levels...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Focal Adhesion Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Focal Adhesion Protein-Tyrosine Kinases

Share to Imidazoles

Share to Mesothelioma

Share to Proto-Oncogene Proteins c-mdm2

Share to Pyrazines

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 41729969
DOI: 10.1371/journal.pone.0343551
PMCID: PMC12928570

Genes

MDM2
TP53
NF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Strategic selection of MDM2 inhibitors enhances the efficacy of FAK inhibition in mesothelioma based on TP53 genotype.PMID 41729969Read ↗

Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.Semantic proximity Read ↗

Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype.Semantic proximity Read ↗

Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAKSemantic proximity Read ↗

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.Semantic proximity Read ↗

NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.Semantic proximity Read ↗

NF2 alteration in mesotheliomaSemantic proximity Read ↗

Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.Semantic proximity Read ↗

Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.Semantic proximity Read ↗

Functional inactivation of NF2/merlin in human mesotheliomaSemantic proximity Read ↗

Kindlin‐2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migrationSemantic proximity Read ↗

Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation.Semantic proximity Read ↗

E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.